With a market capitalization (market cap) of $1.3B — a measure of how much the company is worth — Novavax, Inc. is the 2410th most valuable company in Healthcare as of August 18, 2026. Shares trade at $7.93, down +1.73% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Visit websiteAs of August 18, 2026, Novavax, Inc. (NVAX) is worth $1.3B — this is its market capitalization, the total value of all its outstanding shares.
Novavax, Inc.’s market cap is $1.3B, which ranks it #2410 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Novavax, Inc. (NVAX) shares trade at $7.93, down 1.73% on the day, as of August 18, 2026.
Novavax, Inc. trades at a price-to-earnings (P/E) ratio of 2.9, based on its latest share price and annual earnings per share.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025